Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus FOAMICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus FOAMICON.
CAPEX vs FOAMICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Adults: 200 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid